Concepedia

FCGR3A-158 polymorphism influences the biological response to infliximab in Crohn’s disease through affecting the ADCC activity

Rintaro Moroi, Katsuya Endo, Yoshitaka Kinouchi, Hisashi Shiga, Yoichi Kakuta, Masatake Kuroha, Yoshitake Kanazawa, Yosuke Shimodaira, Takahiko Horiuchi, Seiichi Takahashi,

Immunogenetics · 2013 · 75 citations · 19 references

DOI

Concepts

References

19

A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease

Stephan R. Targan, Stephen B. Hanauer, Sander J. H. van Deventer et al. · New England Journal of Medicine · 1997 · 3.2K citations · Full text

, , +12

Infliximab for the Treatment of Fistulas in Patients with Crohn's Disease

Daniel H. Present, Paul Rutgeerts, Stephan Targan et al. · New England Journal of Medicine · 1999 · 2.7K citations · Full text

, , +14

Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets

Raphael Clynes, Terri L. Towers, Leonard G. Presta et al. · Nature Medicine · 2000 · 2.7K citations

, , +15

Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial

Ravinder N. Maini, E. William St. Clair, Ferdinand C. Breedveld et al. · The Lancet · 1999 · 2.4K citations

, , +17

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene

Guillaume Cartron, Laurent Dacheux, Gilles Salles et al. · Blood · 2002 · 1.9K citations · Full text

, , +16